medRxiv
August 12, 2026
Scott M. Thompson, Devin P. Effinger, Andrew M Novick et al.
preprint
Abstract Oregon (OR) and Colorado (CO) were the first states to enact regulations for provision of psilocybin with support of licensed ‘facilitators.’ As more states and countries adopt similar policies, informed public policy decisions require that client characteristics and rationale for using psilocybin, psilocybin dosing practices, mental health outcomes, and adverse events are understood....
Drugs and Drug Candidates
August 12, 2026
M. Salgaço, D. D. Farias, Mariela Zucolo de Souza et al.
Background/Objectives: This study investigated the effects of a single dose of psilocybin-containing Psilocybe cubensis extract on gut microbiota composition, microbial metabolism, and intestinal immune-related responses. Methods: A single dose of P. cubensis extract (35 mg/L) was subjected to colonic fermentation using the SHIME® model inoculated with fecal microbiota from individuals with...
bioRxiv
August 12, 2026
preprint
Investigating the Effects of Psilocybin on Cognitive Flexibility in Touchscreen and Naturalistic Variations of the Probabilistic Reversal Learning Task
Journal of Clinical Medicine
August 12, 2026
Teodora Anghel, Adriana Cojocaru, Lavinia Hogea et al.
Background/Objectives: Psilocybin-assisted therapy has progressed from early proof-of-concept work to a substantially expanded evidence base, with four pivotal studies published in 2025–2026 that were not incorporated into earlier reviews. This review synthesizes the pharmacological and neurobiological foundations of psilocybin and appraises clinical evidence across major depressive disorder...
Acta Crystallographica Section C Structural Chemistry
August 7, 2026
Sonya K. Emmett, Lee Cameron, Mark Hestermann et al.
The crystal structure of the known low-temperature anhydrous phase of psilocybin {3-[2-(dimethylamino)ethyl]-1H-indol-4-yl dihydrogen phosphate, C12H17N2O4P} is reported. While the structure was previously characterized using powder X-ray diffraction, this study describes the first determination via single-crystal X-ray diffraction. High-resolution structural models were obtained both before...
CNS Drugs
August 7, 2026
Chiranth Bhagavan, Olivia Carter, Glenn Nielsen et al.
BACKGROUND: Psychedelics exert widespread effects on brain activity, but their impact on motor function is unclear. This is clinically relevant given the emerging interest in psychedelic-assisted physical therapy for disorders of motor function. This study examined the feasibility and safety of administering movement tasks following low-to-moderate doses of psilocybin in healthy volunteers....
Nature Medicine
August 6, 2026
James Rucker, Tim Mantingh, Jess Kerr-Gaffney et al.
1 citation
Psilocybin-assisted therapy may be a promising new treatment for treatment-resistant depression. We examined the feasibility of administering a single 25-mg dose of psilocybin or placebo with psychological support in a randomized controlled trial design with 6 weeks of follow-up. A two-arm, double-blind, randomized, placebo-controlled feasibility trial was conducted at one National Health...
The Brown University Psychopharmacology Update
August 3, 2026
Individuals with cocaine use disorder who received a single dose of psilocybin combined with psychotherapy showed greater reductions in cocaine use relative to active placebo with psychotherapy, a randomized trial has found. No serious adverse events were reported during the trial.
British Journal of Mental Health Nursing
August 2, 2026
Rachel Sinclair
Depression remains a significant public health concern worldwide and many individuals do not achieve adequate symptom relief from conventional treatments such as antidepressants and psychological therapies. Interest has therefore increased in alternative interventions, including psilocybin microdosing. This article aimed to critically review the current evidence regarding the use of psilocybin...
Journal of Pain
August 1, 2026
Jon G Dean, Ethan Hurwitz, T. Furnish et al.
Phantom limb pain (PLP) is a refractory condition defined by pain experienced in a missing limb. Psilocybin, a classical serotonergic psychedelic drug, can alleviate various treatment-resistant disorders but has scantly been investigated for chronic pain. This placebo-controlled, double-blind, randomized clinical pilot trial (NCT05224336) tested the feasibility, tolerability, and preliminary...